Blogs
May 12, 2026
Companies Act 2013 Section 197 caps managerial pay at 11% of PAT. Learn how to read this under-used governance ratio in 15 minutes — illustrated by Titan Biotech FY25's ~₹4.56 Cr director remuneration alongside 14 board meetings, an independent chair, ~103% CFO/Operating Profit and a ~29% ten-year PAT CAGR.
May 12, 2026
Why time arbitrage — the structural edge of holding quality businesses for five to ten years while institutional money is forced to optimise for the next 90 days — is the rarest source of edge in Indian value investing, illustrated by Titan Biotech's FY25 audited numbers.
May 11, 2026
Edward Thorndike documented the halo effect in 1920; Phil Rosenzweig's 2007 book showed it runs backward in business commentary. We unpack the five Indian retail-investor halo channels, share a five-step de-haloing checklist, and use Titan Biotech FY25's nine decorrelated disclosed markers as an illustrative anti-halo process case study.
May 11, 2026
How to read a 10-year Revenue CAGR through four disciplined lenses — illustrated with Titan Biotech FY25 audited numbers (~15% Revenue CAGR, ~29% PAT CAGR, ~103% CFO/OP, Rs.3 Cr borrowings). Educational only.
